论文部分内容阅读
目的探讨黏膜黏附化疗药物HPC-MMC预防肿瘤复发的效果。方法对46例表浅膀胱癌患者于TURBt术后随机分两组行膀胱灌注化疗,黏膜黏附化疗药物组20例,以20mg/20ml1%HPC-MMC膀胱灌注;MMC组26例,以20mg/20mlMMC膀胱灌注。疗程1年。HPC-MMC组总灌注次数少于MMC组4次。随访6~36个月。结果HPC-MMC组未发现出血性膀胱炎,无明显尿路刺激症状。平均随访27.4个月,7例复发,1年复发率为16.7%,3年总复发率38.9%。MMC组平均随访26.8个月,9例复发,1年复发率为22.7%,3年总复发率40.9%。结论黏膜黏附化疗药物HPC-MMC膀胱灌注防止肿瘤复发优于单用MMC,同时可降低副作用,减轻患者痛苦及经济负担。
Objective To investigate the effect of mucosal adhesion chemotherapy HPC-MMC in preventing tumor recurrence. Methods Twenty-six patients with superficial bladder cancer were randomly divided into two groups. Twenty patients with superficial bladder cancer were treated with intravesical chemotherapy and 20 with 20mg / 20ml 1% HPC-MMC intravesical instillation. Sixteen patients with MMC were treated with 20mg / 20ml MMC Bladder perfusion. Treatment for 1 year. The total number of perfusion in HPC-MMC group was less than that in MMC group 4 times. Follow-up 6 to 36 months. Results HPC-MMC group did not find hemorrhagic cystitis, no obvious urinary tract irritation. With an average follow-up of 27.4 months, 7 patients relapsed. The 1-year recurrence rate was 16.7% and the 3-year total relapse rate was 38.9%. The average follow-up of 26.8 months in MMC group was 9 months. The recurrence rate was 22.7% at 1 year and 40.9% at 3 years. Conclusions Bladder adhesion of mucosal adhesion chemotherapeutic drugs (HPC-MMC) can prevent tumor recurrence better than MMC alone, reduce side effects and alleviate patients’ pain and financial burden.